ESR1 and prostate carcinoma: For this reason, selective estrogen receptor modulators (SERMs), such as raloxifene, have been tested in AR-(PC3, DU-145) and AR+ (LnCaP) prostate cancer cells inducing apoptosis at micromolar concentrations [13].